Investigational drug · Phase 3
SR604
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Factor VII Deficiency, Hemophilia A, Hemophilia B.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "SR604"
First trial start
2024
May 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SR604", any sponsor or status.
Conditions studied
As listed on its trial records.
- Factor VII Deficiency
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease (VWD)
- Hemophilia A and B
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SR604" as an intervention, largest first.
- A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With HemophiliaPivotal-lookingNot yet recruiting
Shanghai RAAS Blood Products Co., Ltd.Industry
NCT07876674 · 90 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2027
Drug: SR604 · For: Hemophilia A; Hemophilia A and B; Hemophilia B
Shanghai RAAS Blood Products Co., Ltd.Industry
NCT07644832 · 76 participants (planned) · Start May 31, 2024 · Primary completion Dec 31, 2026
Drug: SR604; SR604 and 1 more · For: Hemophilia A; Hemophilia B; Factor VII Deficiency
Sites: Changsha, China; Hefei, China; Jinan, China · 9 sites in all
Equilibra Bioscience LLCIndustry
NCT06349473 · 31 participants (planned) · Start May 10, 2024 · Primary completion Sep 28, 2026
Drug: SR604; Placebo · For: Healthy Participants; Hemophilia A; Hemophilia B and 1 more
Sites: Glendale, California; Los Angeles, California; Chicago, Illinois · 10 sites in all
Shanghai RAAS Blood Products Co., Ltd.Industry
NCT07640893 · 24 participants (planned) · Start Nov 26, 2025 · Primary completion Dec 31, 2027
Drug: SR604 · For: Von Willebrand Disease (VWD)
Sites: Changsha, China; Hefei, China; Jinan, China · 9 sites in all
- A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII DeficiencyNot yet recruiting
Shanghai RAAS Blood Products Co., Ltd.Industry
NCT07711158 · 12 participants (planned) · Start Jul 2026 · Primary completion Feb 2027
Drug: SR604 · For: Factor VII Deficiency
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- Innovations in Haemostasis Management in China: From Gene Therapy to Novel Rebalancing Strategies.
Liu W, Xiao X, Xu J, et al. · Haemophilia 2026
- Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.
Jiang M, Yang F, Jiang Y, et al. · Blood 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.